Search

Your search keyword '"Ahmed A. El-Ray"' showing total 3 results
Start Over Author "Ahmed A. El-Ray" Publisher elsevier
3 results on '"Ahmed A. El-Ray"'

1. Eosinophilic ascites as an uncommon presentation of eosinophilic gastroenteritis: A case report.

Author

El Ray A, Montasser A, El Ghannam M, El Ray S, and Valla D

Subjects
Adult, Ascites, Egypt, Female, Gastritis, Humans, Enteritis, Eosinophilia
Abstract

Background: Eosinophilic gastroenteritis (EGE) is defined by the presence of gastrointestinal symptoms, with an abnormal eosinophilic infiltrate of the intestine wall and exclusion of other causes of secondary eosinophilia. EGE has three clinical presentations, depending on the depth of eosinophilic infiltration of the bowel wall. It individualizes into three types, namely mucosal, muscular, and subserosal. Eosinophilic ascites, which is caused by edema and eosinophilic inflammation of the serosal layer of the small bowel wall, is the most uncommon presentation of EGE., Case Summary: A 30-year-old Egyptian woman presented with pain in the epigastrium and diffuse abdominal distension. Past medical history comprised allergy to iron injections (for iron deficiency anemia). Clinical examination showed moderate abdominal distention (palpation) and shifting dullness (percussion) suggestive of moderate ascites; mild right pleural effusion was also suspected, but findings were otherwise unremarkable. Abdominal and pelvic examinations by ultrasound and contrast-enhanced computed tomography showed moderate ascites, mild right pleural effusion, and diffuse thickening of the antrum and small bowel loops. Endoscopy of the upper gastrointestinal tract revealed mild diffuse hyperemia of the esophagus, stomach and duodenum, with no relevant findings in the histopathology of biopsy specimens taken from these sites. Laboratory results showed eosinophilia in the peripheral blood and marked increase of eosinophils in the ascitic fluid. Treatment with corticosteroids resulted in normalization of the laboratory test results, and the ascites resolved within a week of initiation of therapy., Conclusion: Eosinophilic ascites, characterized by increased eosinophils in peripheral blood and ascitic fluid, showed dramatic response to steroid therapy., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.)

Published
2021
Full Text
View/download PDF

2. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

Author

Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, El Ray A, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, and Marcellin P

Subjects
Adult, Aged, Cohort Studies, Female, Genotype, Hepacivirus drug effects, Humans, Interferon-alpha administration & dosage, Interferons, Male, Middle Aged, Polymorphism, Single Nucleotide, Precision Medicine methods, Retrospective Studies, Ribavirin administration & dosage, Severity of Illness Index, Viral Load drug effects, Young Adult, Antiviral Agents administration & dosage, Drug Resistance, Viral genetics, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic genetics, Interleukins genetics
Abstract

Background & Aims: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections. However, there are few data on HCV genotype 4 (HCV-4) infection. We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity., Methods: This study included 164 HCV-4 patients from different ethnic groups (Egyptian, European, and Sub-Saharan African). Among these patients, 82 were studied for response and 160 for disease severity. Free DNA extracted from all the 164 patient's serum samples was analyzed by direct sequencing of the SNP rs12979860 of IL28B. Genetic and bio-clinical features from patients having sustained virological response (43 SVR patients) and from those who did not respond to treatment or had a relapse after the end of the treatment (39 NR patients) were compared. IL28B polymorphism was compared between the 78 patients with mild fibrosis (Metavir score F0-F1) and the 82 with advanced fibrosis (F2-F4)., Results: Our data showed a better treatment response rate of the C allele of the IL28B gene SNP rs12979860 (p=0.0008). The response rates were 81.8%, 46.5%, and 29.4% for genotype CC, CT, and TT, respectively. No significant relationship was found between rs12979860 and the severity of the disease., Conclusions: The SNP rs12979860 is strongly associated with SVR in patients infected with HCV-4, but not with liver disease severity. Analysis of IL28B genotype might be used to guide treatment for these patients., (Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Published
2012
Full Text
View/download PDF

3. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.

Author

Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, El Ray A, Cazals-Hatem D, Vidaud D, Valla D, Bourlière M, and Marcellin P

Subjects
Drug Therapy, Combination, Female, Humans, Interferon alpha-2, Kinetics, Male, Middle Aged, Polyethylene Glycols, Predictive Value of Tests, Recombinant Proteins, Recurrence, Retreatment, Time Factors, Treatment Failure, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Hepacivirus drug effects, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Interferon-alpha therapeutic use, Ribavirin therapeutic use
Abstract

Background/aims: To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of trials, who were relapsers or non-responders to interferon and ribavirin combination., Methods: One hundred and fifty-four patients were evaluated. There were 101 non-responders and 53 relapsers to standard combination therapy. Patients were retreated with peginterferon alfa-2b 1.5 microg/kg/wk plus ribavirin 1000-1200 mg/day during 48 weeks., Results: Forty-four patients (28.6%) achieved sustained virological response (SVR). Rapid (week 4) and early (week 12) virological response had high negative predictive values of SVR (94% and 97%, respectively); however positive predictive values were relatively low (52% and 49%, respectively). Relapsers had higher SVR rates (58.5%) than non-responders (13%) p<0.0001. In non-responders, SVR raised to 50% in patients with genotype non-1 and mild or moderate fibrosis. In multivariate analysis, predictors of SVR were: relapse after interferon plus ribavirin combination, mild or moderate fibrosis, genotype non-1 and baseline viral load <2 million copies/ml., Conclusions: Relapsers to interferon plus ribavirin therapy, and non-responders with genotype non-1 and mild or moderate fibrosis, achieved a relatively high SVR rate following retreatment with peginterferon plus ribavirin. Early viral kinetics had a high negative predictive value of SVR.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results